E-ISSN 1309-4866
Research Article
Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders
1 Department of Neurology, Bezmialem Vakif University School of Medicine, İstanbul, Turkey  
2 Department of Maxillofacial Surgery, İstanbul University İstanbul School of Dentistry, İstanbul, Turkey  
3 Department of Neurology, İstanbul University İstanbul School of Medicine, İstanbul, Turkey  
4 Department of Neurology, İstanbul Bilim University School of Medicine, İstanbul, Turkey  
5 Neurology, Private Practice, İstanbul, Turkey  
Arch Neuropsychiatry ; : -
DOI: 10.5152/npa.2017.19257
This article was viewed 66 times, downloaded 0 times

Key Words: Temporomandibular disorders, headache, onabotulinumtoxinA, chronic migraine

Introduction: Migraine and temporomandibular disorders (TMD) are both common diseases and TMD are reported as a risk factor in migraine progression. OnabotulinumtoxinA is used in the treatment of chronic migraine (CM) and also has a potential role in TMD treatment. In this study, it is aimed to compare the efficacy of onabotulinumtoxinA treatment in CM patients with and without TMD.


Methods: In this retrospective study, 30 CM patients (age range: 18- 65 years), satisfying the inclusion and follow-up criteria in their medical records were investigated. The PREEMPT injection protocol was taken as reference and onabotulinumtoxinA 155-195 U with fixed-dose has been administered into 31 specific sites within the head/neck muscles in included subjects. Two cycles of treatment were assessed in all patients at the baseline and 12 weeks later. The headache diaries, which were completed routinely one month before, and during 6 months follow-up after the treatment, were assessed. The effect of onabotulinumtoxinA treatment was compared between CM patients with and without TMD/bruxism.


Results: Of 30 female patients, 17 had concomitant TMD. In week 24, there were significant improvement in the groups with and without TMD regarding to the mean change of frequencies in the days with migraine compared to the initial findings (p<0.001). However, there was no significant difference between the two groups.



Conclusions: OnabotulinumtoxinA is an effective and safe treatment for CM. Its efficacy appears to be similar in CM patients with and without TM, speculating that the comorbidity of TMD did not play a role for the treatment response.

Key Words
Author's Corner
Latest Update: 29.12.2017